Immunocompromised people make up less than three percent of the United States adult population. However, they account for forty-five percent of breakthrough COVID-19 infections. The Centers for Disease Control and Prevention recommended that people who are moderately to severely immunocompromised get a third dose of the COVID-19 vaccine. A team of researchers at Michigan Medicine will co-lead a national trial to determine the effectiveness of a third dose.
Use promo code GOBLUE to receive an exclusive discount